Gastrointestinal parasites are among the most common and chronic health problems of dogs globally. From roundworms hiding in tainted soil to heartworm larvae passed by mosquitoes, intestinal parasites may wreak havoc on a dog's digestive tract, cardiovascular system and general health without anyone knowing. Pet owners and veterinary experts have long been looking for a safe, easy and wide range solution. Afoxolaner and milbemycin oxime chewable tablets have developed as a scientifically validated solution to this dilemma, providing dual-action protection in a single monthly dosage.
In this article, we'll look at how this combination works, why it has become a trusted standard in veterinary parasite care, and how monthly preventative programs based on this formulation are revolutionising the way dog owners safeguard their animals.
Afoxolaner And Milbemycin Oxime Chewable Tablets
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
9.375+1.875mg：2-3.5kg
18.75+3.75mg：＞3.5-7.5kg
37.5+7.5mg：＞7.5-15kg
75+15mg：＞15-30kg
150+30mg：＞30-60kg
(3)Ointment
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-117
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
How Do Afoxolaner and Milbemycin Oxime Work Against Gastrointestinal Parasites in Dogs?
The Role of Milbemycin Oxime in Targeting Internal Parasites
Milbemycin oxime is the principal workhorse in the gastrointestinal parasite control portion of this combo formulation. As a macrolide anthelmintic it acts on glutamate-gated chloride channels which are only present in invertebrate nerve and muscle cells. Milbemycin oxime, once bound to these channels, increases membrane permeability and induces hyperpolarisation of neuromuscular cells and eventually paralysis and death of sensitive parasites.
This process is quite selective. Milbemycin oxime is fatal to the parasites and does not significantly affect canine neurological function. In animals the blood-brain barrier has very poor permeability to milbemycin oxime.
This form of action is very useful against gastrointestinal nematodes such as Toxocara canis, Ancylostoma caninum and Trichuris vulpis.
Why the Combination with Afoxolaner Matters
Afoxolaner is targeting a different danger. It functions as an isoxazoline insecticide and acaricide by blocking GABA-gated chloride channels in arthropods like fleas and ticks. Afoxolaner is not a direct-acting anti-nematode, but the inclusion of afoxolaner in the afoxolaner and milbemycin oxime chewable tablets guarantees simultaneous elimination of ectoparasites that may act as intermediary hosts or vectors for certain internal parasitic illnesses. This co-action minimises the total parasite load on the dog and helps in achieving a more comprehensive protective effect.
The Dual Mechanism Behind Afoxolaner and Milbemycin Oxime for Internal Parasite Control
Two Active Ingredients, One Coordinated Defense
Milbemycin oxime is a mixture of two components – A3 (about 20%) and A4 (roughly 80%) – which have somewhat distinct pharmacokinetic characteristics. After oral dosing, milbemycin A3 achieves peak plasma levels at 1 to 2 hours and has a half-life of around 1.6 days. Milbemycin A4 reaches the peak at a comparable time but has a longer half-life of around 3.3 days. The staggered elimination of these drugs allows for effective antiparasitic drug concentrations to be maintained over the month between doses .
Conversely, afoxolaner has a much longer half-life in plasma, about two weeks, with peak concentration occurring within two to four hours after consumption.
It has an absolute bioavailability of 88% in dogs, making it one of the most dependably absorbed antiparasitic compounds known.
Pharmacokinetics That Support Monthly Dosing
The pharmacokinetics of both active compounds are particularly designed to allow for once monthly oral delivery. Studies show that an oral dose in dogs produces a peak plasma concentration of 1,822 ± 165 ng/mL of afoxolaner and a volume of distribution in tissue of 2.6 ± 0.6 L/kg. The data suggest a chemical with widespread tissue distribution throughout the body and a prolonged duration of clinically efficacious levels. Pet owners may offer afoxolaner and milbemycin oxime chewable tablets to their pets on a monthly basis, since the half-life of both active ingredients overlap, providing a continuous window of protection against internal and external parasites.
Afoxolaner and Milbemycin Oxime: Targeting Nematodes Through Advanced Antiparasitic Action
Specific Nematode Species Addressed by Milbemycin Oxime
Milbemycin oxime has been shown to be active against a number of common gastrointestinal nematode species in dogs. Toxocara canis (roundworm), Toxascaris leonina, Ancylostoma caninum (hookworm), Trichuris vulpis (whipworm). Its anthelmintic activity includes: Outside the GI tract, it is also helpful in avoiding Dirofilaria immitis (heartworm) infection, by destroying third- and fourth-stage larvae before they develop in the circulatory system. This makes it especially useful in parts of the world where heartworm is common.
Drug Resistance Considerations and Clinical Vigilance
The establishment of anthelmintic resistance in nematode populations is attracting growing attention from veterinary doctors. Milbemycin oxime is a macrolide medication that is chemically different from benzimidazoles and pyrimidines. Milbemycin oxime may be an option in dogs who have had a poor response to traditional anthelmintics but veterinary drug sensitivity testing is still recommended prior to treatment replacement. The use of afoxolaner and milbemycin oxime chewable tablets on a consistent monthly basis also reduces selective pressure by providing sustained parasite suppression versus cyclical re-infestation.
Why Veterinarians Choose Afoxolaner and Milbemycin Oxime for Comprehensive Dog Parasite Management
Clinical Confidence Built on Pharmacological Evidence
The combination formulation appeals to veterinary specialists because of its proven evidence-based effectiveness against many groups of parasites at the same time. One chewable tablet a month handles both external and internal parasites instead of using various treatments at different times. Clinical pharmacology results are supportive of the safety profile of this formulation in most dog breeds except in dogs with the MDR1 gene mutation (certain Collie lines) where drug buildup may develop and veterinarian supervision on the dose is needed.
Breed and Weight-Specific Dosing Precision
The formulation is available in five weight specific formulations, for dogs from 2kg to 60kg and beyond. The dosage of afoxolaner (9.375 mg to 150 mg per tablet) with milbemycin oxime (1.875 mg to 30 mg) is medically adequate for each dog for body weight. For dogs above 50 kg, higher quality tablet combinations enable exact dosage calculation within the safe and effective range of 2.5–6.9 mg/kg afoxolaner. Such precise dosage is indicative of the scientific rigour that went into the creation of the medication.
Afoxolaner and Milbemycin Oxime Applications in Monthly Gastrointestinal Parasite Prevention Programs
Building a Year-Round Prevention Protocol
The current gold standard in veterinary parasitology is monthly parasite prevention regimens. Afoxolaner and milbemycin oxime chewable tablets provide continuous systemic protection against heartworm larvae, gastrointestinal nematodes, fleas and ticks when given on the same calendar date each month. This regularity is particularly important during warmer months when parasite transmission rates are greatest, but year-round administration is generally suggested since gastrointestinal nematode eggs may survive in the environment regardless of season.
Practical Considerations for Pet Owners and Veterinary Clinics
The pleasant chewable version is far more acceptable to owners and dogs than typical tablet formulations.Tablets may be given straight as a treat or mixed with a tiny bit of food to ensure the whole dose is taken. Owners must ensure that all of the tablet has been eaten before stopping monitoring of feeding. Keep any unused pieces in original packaging and out of reach of youngsters and hands should be cleansed thoroughly after handling. Administration is not recommended in dogs younger than 8 weeks of age or weighing less than 2 kg. Use of this formulation in pregnant or lactating dogs should be under the direct supervision of a veterinarian since safety data are lacking in these groups.
Conclusion
Afoxolaner and milbemycin oxime are scientifically proven, clinically confirmed, broad-spectrum parasite treatment options for dogs. This formulation combines the activity of the glutamate-gated chloride channel of milbemycin oxime with the GABA-inhibiting activity of afoxolaner to provide broad spectrum protection against gastrointestinal nematodes, heartworm larvae, fleas and ticks in a single monthly chewable tablet with afoxolaner and milbemycin oxime chewable tablets. It is a logical candidate for both regular prophylaxis and for directed treatment programs, given its well-understood pharmacokinetics, weight-based dosage approach, and established safety profile.
FAQ
Q1: What gastrointestinal parasites do afoxolaner and milbemycin oxime chewable tablets protect against?
+
-
The milbemycin oxime component is efficacious against a number of common canine gastrointestinal nematodes including Toxocara canis, Ancylostoma caninum and Trichuris vulpis. It kills sensitive larval stages before to adulthood, therefore preventing Dirofilaria immitis (heartworm) infection. This makes the formulation an all-in-one internal parasite control alternative in one monthly dosage.
Q2: Is it safe to use afoxolaner and milbemycin oxime chewable tablets in all dog breeds?
+
-
The formulation was well tolerated in most breeds of dogs at body weight-based doses. Some breeds, such as some Collie lines, that are known to contain the MDR1 gene mutation may have altered P-glycoprotein activity and metabolise milbemycin oxime differently, perhaps resulting in increased drug concentrations. These breeds need to be seen by a vet prior to treatment being started.
Q3: How often should afoxolaner and milbemycin oxime chewable tablets be administered for gastrointestinal parasite prevention?
+
-
The usual dose frequency is once a month by mouth. The pharmacokinetic characteristics of the two active ingredients, especially the longer half-life of afoxolaner (about 2 weeks) and the persistent action of milbemycin A4 (half-life of 3.3 days), are tailored to maintain protective plasma concentrations throughout the whole monthly period. For optimum results against gastrointestinal and systemic parasites, year-round dosing is suggested.
Partner with Bloomtechz for Reliable Afoxolaner and Milbemycin Oxime Chewable Tablets Supply
At Bloomtechz, we know that quality and consistency are non-negotiable as it pertains to veterinary pharmaceutical procurement. We are a reliable provider of afoxolaner and milbemycin oxime chewable tablets, with a 100,000 square meters GMP-certified manufacturing base, and certifications from US FDA, EU GMP, JP and CFDA. We have a triple layer quality control system including factory inspection, in-house QA/QC review and third party authority verification to guarantee each batch meets the highest international standards.
If you're a pharmaceutical distributor, veterinary clinic network or wholesale trading organization in the USA, Australia, Japan, Germany, Brazil or beyond, Bloomtechz provides accurate lead times, affordable pricing and full paperwork for smooth customs clearance. Clients with particular branding or formulation requirements may also benefit from OEM and ODM customisation possibilities.
Ready to discuss your sourcing requirements? Reach out to our team directly at Sales@bloomtechz.com. We look forward to building a long-term, transparent supply partnership with you.
References
1. Prichard, R., & Tait, A. (2001). The role of molecular biology in veterinary parasitology. Veterinary Parasitology, 98(1–3), 169–194.
2. Rufener, L., Danelli, V., Bertrand, D., & Sager, H. (2017). The novel isoxazoline ectoparasiticide afoxolaner is a potent blocker of arthropod ligand-gated chloride channels. Pesticide Biochemistry and Physiology, 138, 74–80.
3. Cully, D. F., Vassilatis, D. K., Liu, K. K., Paress, P. S., Van der Ploeg, L. H., Schaeffer, J. M., & Arena, J. P. (1994). Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature, 371(6499), 707–711.
4. Wolstenholme, A. J., & Rogers, A. T. (2005). Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology, 131(Suppl), S85–S95.
5. Dryden, M. W., Payne, P. A., Ridley, R., & Smith, V. (2005). Comparison of common flea and tick control products with a novel isoxazoline compound in client-owned dogs. Veterinary Parasitology, 130(3–4), 249–260.
6. Lanusse, C. E., Lifschitz, A. L., & Imperiale, F. A. (2009). Macrolide antibiotics and related compounds. In Veterinary Pharmacology and Therapeutics (9th ed., pp. 1119–1143). Wiley-Blackwell.